Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients

J Zhejiang Univ Sci B. 2020;21(9):740-744. doi: 10.1631/jzus.B1900719.

Abstract

Acute lymphocytic leukemia (ALL) is one of the most common malignancies, especially in young people. Combination chemotherapy for ALL typically includes corticosteroids (Kantarjian et al., 2000). Hyperglycemia is a well-recognized complication of corticosteroids, and chemotherapy-induced diabetes (CID) is not uncommon (27.5%-37.0%) during the treatment of ALL (Hsu et al., 2002; Weiser et al., 2004; Alves et al., 2007). Besides the effect of corticosteroids, potential factors triggering hyperglycemia in ALL also include direct infiltration of the pancreas by leukemia cells and β cell dysfunction induced by chemotherapeutic agents such as L-asparagine (Mohn et al., 2004).

Keywords: Acute lymphoblastic leukemia; Diabetes mellitus; Clinical characteristics.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Diabetes Mellitus / chemically induced*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Young Adult

Substances

  • Antineoplastic Agents